First Quadrant’s Vertex Pharmaceuticals VRTX Stock Holding History

First Quadrant’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,024	Closed	-$1.54M	–	518
2021 Q4	$1.54M	Hold	7,024	–	–	0.17%	123
2021 Q3	$1.27M	Buy	7,024 +2,400	+52%	+$469K	0.15%	133
2021 Q2	$932K	Sell	4,624 -3,671	-44%	-$768K	0.11%	175
2021 Q1	$1.78M	Sell	8,295 -5,274	-39%	-$1.16M	0.19%	113
2020 Q4	$3.21M	Sell	13,569 -1,465	-10%	-$336K	0.32%	51
2020 Q3	$4.09M	Sell	15,034 -2,003	-12%	-$553K	0.52%	32
2020 Q2	$4.95M	Sell	17,037 -5,952	-26%	-$1.61M	0.66%	25
2020 Q1	$5.47M	Buy	22,989 +11,368	+98%	+$2.61M	0.8%	20
2019 Q4	$2.54M	Sell	11,621 -6,198	-35%	-$1.25M	0.21%	102
2019 Q3	$3.02M	Sell	17,819 -845	-5%	-$149K	0.28%	90
2019 Q2	$3.42M	Buy	18,664 +12,360	+196%	+$2.16M	0.24%	104
2019 Q1	$1.16M	Sell	6,304 -878	-12%	-$162K	0.09%	239
2018 Q4	$1.19M	Sell	7,182 -127,235	-95%	-$22M	0.1%	214
2018 Q3	$25.9M	Sell	134,417 -58,510	-30%	-$10.4M	0.58%	30
2018 Q2	$32.8M	Buy	192,927 +1,298	+0.7%	+$201K	0.61%	30
2018 Q1	$31.2M	Buy	191,629 +55,646	+41%	+$9.09M	0.6%	23
2017 Q4	$20.4M	Buy	135,983 +6,168	+5%	+$913K	0.38%	88
2017 Q3	$19.7M	Buy	129,815 +127,856	+6,527%	+$19.2M	0.38%	85
2017 Q2	$252K	Buy	1,959 +1,459	+292%	+$176K	0.01%	649
2017 Q1	$55K	Hold	500	–	–	﹤0.01%	745
2016 Q4	$37K	Hold	500	–	–	﹤0.01%	782
2016 Q3	$44K	Hold	500	–	–	﹤0.01%	796
2016 Q2	$43K	Hold	500	–	–	﹤0.01%	720
2016 Q1	$40K	Buy	+500	New	+$45.2K	﹤0.01%	701
2015 Q4	–	Sell	-400	Closed	-$42K	–	844
2015 Q3	$42K	Buy	400 +200	+100%	+$25.7K	﹤0.01%	692
2015 Q2	$25K	Buy	+200	New	+$25.2K	﹤0.01%	729

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

First Quadrant's VRTX Position: Q1 2022 in Review

First Quadrant sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 7,024 shares — an estimated $1.54M sold.

First Quadrant first reported a position in VRTX in Q2 2015 and held it in 26 quarters. The position peaked at $32.8M in Q2 2018. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

First Quadrant reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 7,024 Vertex Pharmaceuticals shares in Q1 2022, an estimated $1.54M.
First Quadrant first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 26 quarters.
First Quadrant's Vertex Pharmaceuticals position peaked at $32.8M in Q2 2018.
1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.